The effectiveness of fingolimod in a Portuguese real-world population
- 1 March 2016
- journal article
- clinical trial
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 6, 41-48
Abstract
No abstract availableKeywords
Funding Information
- Biogen
This publication has 18 references indexed in Scilit:
- Switching from natalizumab to fingolimodNeurology, 2015
- Experience with fingolimod in clinical practiceInternational Journal of Neuroscience, 2014
- Real-World Use of Fingolimod in Patients with Relapsing Remitting Multiple Sclerosis: A Retrospective Study Using the National Multiple Sclerosis Registry in KuwaitCNS Drugs, 2014
- Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trialThe Lancet Neurology, 2014
- Switching From Natalizumab to Fingolimod in Multiple SclerosisJAMA Neurology, 2014
- A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple SclerosisNew England Journal of Medicine, 2010
- Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple SclerosisNew England Journal of Medicine, 2010
- FTY720 (fingolimod) in Multiple Sclerosis: therapeutic effects in the immune and the central nervous systemBritish Journal of Pharmacology, 2009
- Oral Fingolimod (FTY720) for Relapsing Multiple SclerosisNew England Journal of Medicine, 2006
- Defining the clinical course of multiple sclerosisNeurology, 1996